您好,欢迎访问中国水产科学研究院 机构知识库!

An Avirulent Largemouth Bass Birnavirus Vaccine Candidate Protects Largemouth Bass against Birnavirus Infection

文献类型: 外文期刊

作者: Fu, Xiaozhe 1 ; Luo, Mingju 1 ; Lin, Qiang 1 ; Liang, Hongru 1 ; Niu, Yinjie 1 ; Luo, Xia 1 ; Ma, Baofu 1 ; Li, Ningqiu 1 ;

作者机构: 1.Chinese Acad Fishery Sci, Pearl River Fishery Res Inst, Guangdong Prov Key Lab Aquat Anim Immune Technol &, Minist Agr & Rural Affairs,Key Lab Fishery Drug De, Guangzhou 510380, Peoples R China

关键词: birnavirus; LBBV-GDSS-20180701; largemouth bass; live vaccine

期刊名称:VACCINES ( 影响因子:7.8; 五年影响因子:7.4 )

ISSN:

年卷期: 2023 年 11 卷 12 期

页码:

收录情况: SCI

摘要: Background: Largemouth bass birnavirus (LBBV) disease outbreaks in largemouth bass fingerlings lead to high mortality in China. Therefore, the development of immersion immunization strategies is paramount. Methods: An avirulent LBBV strain was screened using a fish challenge assay. The proliferation dynamics of the avirulent strain were determined in vitro and in vivo. The efficacy of the avirulent vaccine was evaluated using immune gene expression, viral load, and a virus challenge, and the safety was also assessed using a reversion to virulence test. Results: An avirulent virus strain, designated as largemouth bass birnavirus Guangdong Sanshui (LBBV-GDSS-20180701), was selected from five fish birnavirus isolates. The proliferation peak titer was 109.01 TCID50/mL at 24 hpi in CPB cells and the peak viral load was 2.5 x 104 copies/mg at 4 dpi in the head kidneys and spleens of largemouth bass. The largemouth bass that were immersed within an avirulent vaccine or injected with an inactivated vaccine were protected from the virulent LBBV challenge with a relative percent survival (RPS) of 75% or 42.9%, respectively. The expression levels of IL-12, MHCI, MHCII, CD8, CD4, and IgM in the avirulent group were significantly upregulated at a partial time point compared to the inactivated vaccine group. Moreover, the viral load in the avirulent vaccine group was significantly lower than those in the inactivated vaccine group and control group using real-time PCR. Conclusions: LBBV-GDSS-20180701 is a potential live vaccine candidate against LBBV disease.

  • 相关文献
作者其他论文 更多>>